Apogee Therapeutics Inc
APGE
Company Profile
Business description
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Contact
221 Crescent Street
Building 17, Suite 102b
WalthamMA02453
USAT: +1 650 394-5230
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
261
Stocks News & Analysis
stocks
ASX data centre share forecasts AI fuelled earnings surge
AI and cloud demand underpin bullish growth outlook
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,260.90 | 40.40 | 0.44% |
| CAC 40 | 8,315.67 | 18.83 | -0.23% |
| DAX 40 | 26,004.38 | 253.73 | -0.97% |
| Dow JONES (US) | 53,185.90 | 374.09 | -0.70% |
| FTSE 100 | 10,759.23 | 65.03 | -0.60% |
| HKSE | 25,329.73 | 237.26 | -0.93% |
| NASDAQ | 26,370.89 | 31.54 | -0.12% |
| Nikkei 225 | 66,215.34 | 96.59 | -0.15% |
| NZX 50 Index | 13,786.90 | 130.40 | -0.94% |
| S&P 500 | 7,686.14 | 25.62 | -0.33% |
| S&P/ASX 200 | 9,066.70 | 41.70 | 0.46% |
| SSE Composite Index | 3,979.89 | 6.41 | -0.16% |